<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37378376</PMID><DateRevised><Year>2023</Year><Month>07</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2405-8440</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>6</Issue><PubDate><Year>2023</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Heliyon</Title><ISOAbbreviation>Heliyon</ISOAbbreviation></Journal><ArticleTitle>Long COVID treated successfully with antivirals in a rituximab-treated follicular lymphoma patient with persistent negative-antibodies to SARS-CoV2.</ArticleTitle><Pagination><StartPage>e17149</StartPage><MedlinePgn>e17149</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e17149</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.heliyon.2023.e17149</ELocationID><Abstract><AbstractText>Long COVID is a well-known complication to COVID-19 that affect millions of people worldwide and causes wide range of symptoms. We present a rare case of a previously diagnosed follicular lymphoma patient, who had a long COVID with persistent negative SARS-CoV-2 antibodies and required an aggressive antiviral treatment.</AbstractText><CopyrightInformation>&#xa9; 2023 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tayar</LastName><ForeName>Elias</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Hamad Medical Corporation, Doha, Qatar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Isber</LastName><ForeName>Ryan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Binghamton University, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Isber</LastName><ForeName>Nidal</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Richmond University Medical Center, New York, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Heliyon</MedlineTA><NlmUniqueID>101672560</NlmUniqueID><ISSNLinking>2405-8440</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antivirals</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Follicular lymphoma</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword></KeywordList><CoiStatement>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>28</Day><Hour>13</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>28</Day><Hour>13</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>28</Day><Hour>9</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>6</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37378376</ArticleId><ArticleId IdType="pmc">PMC10284434</ArticleId><ArticleId IdType="doi">10.1016/j.heliyon.2023.e17149</ArticleId><ArticleId IdType="pii">S2405-8440(23)04357-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lai C.C., Shih T.P., Ko W.C., Tang H.J., Hsueh P.R. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int. J. Antimicrob. Agents. 2020;55 doi: 10.1016/J.IJANTIMICAG.2020.105924.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.IJANTIMICAG.2020.105924</ArticleId><ArticleId IdType="pmc">PMC7127800</ArticleId><ArticleId IdType="pubmed">32081636</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z., Xie Y., Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nat. 2021;594:259&#x2013;264. doi: 10.1038/s41586-021-03553-9. 2021 5947862.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03553-9</ArticleId><ArticleId IdType="pubmed">33887749</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis H.E., Assaf G.S., McCorkell L., Wei H., Low R.J., Re&#x2019;em Y., Redfield S., Austin J.P., Akrami A. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38 doi: 10.1016/J.ECLINM.2021.101019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.ECLINM.2021.101019</ArticleId><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>New data shows long Covid is keeping as many as 4 million people out of work, (n.d.). https://www.brookings.edu/research/new-data-shows-long-covid-is-keeping-as-many-as-4-million-people-out-of-work/(accessed September 16, 2022).</Citation></Reference><Reference><Citation>Fern&#xe1;ndez-Casta&#xf1;eda A., Lu P., Geraghty A.C., Song E., Lee M.H., Wood J., O'Dea M.R., Dutton S., Shamardani K., Nwangwu K., Mancusi R., Yal&#xe7;&#x131;n B., Taylor K.R., Acosta-Alvarez L., Malacon K., Keough M.B., Ni L., Woo P.J., Contreras-Esquivel D., Toland A.M.S., Gehlhausen J.R., Klein J., Takahashi T., Silva J., Israelow B., Lucas C., Mao T., Pe&#xf1;a-Hern&#xe1;ndez M.A., Tabachnikova A., Homer R.J., Tabacof L., Tosto-Mancuso J., Breyman E., Kontorovich A., McCarthy D., Quezado M., Vogel H., Hefti M.M., Perl D.P., Liddelow S., Folkerth R., Putrino D., Nath A., Iwasaki A., Monje M. Mild respiratory COVID can cause multi-lineage neural cell and myelin dysregulation. Cell. 2022;185:2452&#x2013;2468.e16. doi: 10.1016/J.CELL.2022.06.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.CELL.2022.06.008</ArticleId><ArticleId IdType="pmc">PMC9189143</ArticleId><ArticleId IdType="pubmed">35768006</ArticleId></ArticleIdList></Reference><Reference><Citation>Choutka J., Jansari V., Hornig M., Iwasaki A. Unexplained post-acute infection syndromes. Nat. Med. 2022;285(28):911&#x2013;923. doi: 10.1038/s41591-022-01810-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01810-6</ArticleId><ArticleId IdType="pubmed">35585196</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaebler C., Wang Z., Lorenzi J.C.C., Muecksch F., Finkin S., Tokuyama M., Cho A., Jankovic M., Schaefer-Babajew D., Oliveira T.Y., Cipolla M., Viant C., Barnes C.O., Bram Y., Breton G., H&#xe4;ggl&#xf6;f T., Mendoza P., Hurley A., Turroja M., Gordon K., Millard K.G., Ramos V., Schmidt F., Weisblum Y., Jha D., Tankelevich M., Martinez-Delgado G., Yee J., Patel R., Dizon J., Unson-O&#x2019;Brien C., Shimeliovich I., Robbiani D.F., Zhao Z., Gazumyan A., Schwartz R.E., Hatziioannou T., Bjorkman P.J., Mehandru S., Bieniasz P.D., Caskey M., Nussenzweig M.C. Evolution of antibody immunity to SARS-CoV-2. Nat. 2021;591:639&#x2013;644. doi: 10.1038/s41586-021-03207-w. 2021 5917851.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03207-w</ArticleId><ArticleId IdType="pmc">PMC8221082</ArticleId><ArticleId IdType="pubmed">33461210</ArticleId></ArticleIdList></Reference><Reference><Citation>D C., S S., S R., A G., J C., M S., Ck Y., C W., J D., K Y., Sh K., A P., P B., M Q., S P., M P., V M., F B., M R.-B., E B., D H., J R., K S., R M., A T., S S., M M., K P., J C., de W.E., K V., S H., D K. 2021. SARS-CoV-2 Infection and Persistence throughout the Human Body and Brain.</Citation><ArticleIdList><ArticleId IdType="doi">10.21203/RS.3.RS-1139035/V1</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung C.C.L., Goh D., Lim X., Tien T.Z., Lim J.C.T., Lee J.N., Tan B., Tay Z.E.A., Wan W.Y., Chen E.X., Nerurkar S.N., Loong S., Cheow P.C., Chan C.Y., Koh Y.X., Tan T.T., Kalimuddin S., Tai W.M.D., Ng J.L., Low J.G.H., Yeong J., Lim K.H. Residual SARS-CoV-2 viral antigens detected in GI and hepatic tissues from five recovered patients with COVID-19. Gut. 2022;71:226&#x2013;229. doi: 10.1136/GUTJNL-2021-324280.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/GUTJNL-2021-324280</ArticleId><ArticleId IdType="pubmed">34083386</ArticleId></ArticleIdList></Reference><Reference><Citation>Arostegui D., Castro K., Schwarz S., Vaidy K., Rabinowitz S., Wallach T. Persistent SARS-CoV-2 Nucleocapsid protein presence in the intestinal epithelium of a pediatric patient 3 Months after acute infection. JPGN Reports. 2022;3:e152. doi: 10.1097/PG9.0000000000000152.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PG9.0000000000000152</ArticleId><ArticleId IdType="pmc">PMC10158423</ArticleId><ArticleId IdType="pubmed">37168753</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y., Yuan D., Chen D.G., Ng R.H., Wang K., Choi J., Li S., Hong S., Zhang R., Xie J., Kornilov S.A., Scherler K., Pavlovitch-Bedzyk A.J., Dong S., Lausted C., Lee I., Fallen S., Dai C.L., Baloni P., Smith B., Duvvuri V.R., Anderson K.G., Li J., Yang F., Duncombe C.J., McCulloch D.J., Rostomily C., Troisch P., Zhou J., Mackay S., DeGottardi Q., May D.H., Taniguchi R., Gittelman R.M., Klinger M., Snyder T.M., Roper R., Wojciechowska G., Murray K., Edmark R., Evans S., Jones L., Zhou Y., Rowen L., Liu R., Chour W., Algren H.A., Berrington W.R., Wallick J.A., Cochran R.A., Micikas M.E., Wrin T., Petropoulos C.J., Cole H.R., Fischer T.D., Wei W., Hoon D.S.B., Price N.D., Subramanian N., Hill J.A., Hadlock J., Magis A.T., Ribas A., Lanier L.L., Boyd S.D., Bluestone J.A., Chu H., Hood L., Gottardo R., Greenberg P.D., Davis M.M., Goldman J.D., Heath J.R. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022;185:881&#x2013;895.e20. doi: 10.1016/J.CELL.2022.01.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.CELL.2022.01.014</ArticleId><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehandru S., Merad M. Pathological sequelae of long-haul COVID. Nat. Immunol. 2022;232(23):194&#x2013;202. doi: 10.1038/s41590-021-01104-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01104-y</ArticleId><ArticleId IdType="pmc">PMC9127978</ArticleId><ArticleId IdType="pubmed">35105985</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID Drug May Also Ease Symptoms of Long COVID | UC San Francisco, (n.d.). https://www.ucsf.edu/news/2022/05/422771/covid-drug-may-also-ease-symptoms-long-covid (accessed November 21, 2022).</Citation></Reference><Reference><Citation>Al-Aly Z., Xie Y., Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nat. 2021;594:259&#x2013;264. doi: 10.1038/s41586-021-03553-9. 2021 5947862.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03553-9</ArticleId><ArticleId IdType="pubmed">33887749</ArticleId></ArticleIdList></Reference><Reference><Citation>Long COVID or Post-COVID Conditions | CDC, (n.d.). https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html (accessed September 17, 2022).</Citation></Reference><Reference><Citation>Fern&#xe1;ndez-de-las-Pe&#xf1;as C., Palacios-Ce&#xf1;a D., G&#xf3;mez-Mayordomo V., Florencio L.L., Cuadrado M.L., Plaza-Manzano G., Navarro-Santana M. Prevalence of post-COVID-19 symptoms in hospitalized and non-hospitalized COVID-19 survivors: a systematic review and meta-analysis. Eur. J. Intern. Med. 2021;92:55. doi: 10.1016/J.EJIM.2021.06.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.EJIM.2021.06.009</ArticleId><ArticleId IdType="pmc">PMC8206636</ArticleId><ArticleId IdType="pubmed">34167876</ArticleId></ArticleIdList></Reference><Reference><Citation>Ledford H. Long-COVID treatments: why the world is still waiting. Nature. 2022;608:258&#x2013;260. doi: 10.1038/D41586-022-02140-W.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/D41586-022-02140-W</ArticleId><ArticleId IdType="pubmed">35945375</ArticleId></ArticleIdList></Reference><Reference><Citation>Passamonti F., Cattaneo C., Arcaini L., Bruna R., Cavo M., Merli F., Angelucci E., Krampera M., Cairoli R., Della Porta M.G., Fracchiolla N., Ladetto M., Gambacorti Passerini C., Salvini M., Marchetti M., Lemoli R., Molteni A., Busca A., Cuneo A., Romano A., Giuliani N., Galimberti S., Corso A., Morotti A., Falini B., Billio A., Gherlinzoni F., Visani G., Tisi M.C., Tafuri A., Tosi P., Lanza F., Massaia M., Turrini M., Ferrara F., Gurrieri C., Vallisa D., Martelli M., Derenzini E., Guarini A., Conconi A., Cuccaro A., Cudillo L., Russo D., Ciambelli F., Scattolin A.M., Luppi M., Selleri C., Ortu La Barbera E., Ferrandina C., Di Renzo N., Olivieri A., Bocchia M., Gentile M., Marchesi F., Musto P., Federici A.B., Candoni A., Venditti A., Fava C., Pinto A., Galieni P., Rigacci L., Armiento D., Pane F., Oberti M., Zappasodi P., Visco C., Franchi M., Grossi P.A., Bert&#xf9; L., Corrao G., Pagano L., Corradini P. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol. 2020;7:e737&#x2013;e745. doi: 10.1016/S2352-3026(20)30251-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-3026(20)30251-9</ArticleId><ArticleId IdType="pmc">PMC7426107</ArticleId><ArticleId IdType="pubmed">32798473</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonuomo V., Ferrarini I., Dell'Eva M., Sbis&#xe0; E., Krampera M., Visco C. COVID-19 (SARS-CoV-2 infection) in lymphoma patients: a review. World J. Virol. 2021;10:312. doi: 10.5501/WJV.V10.I6.312.</Citation><ArticleIdList><ArticleId IdType="doi">10.5501/WJV.V10.I6.312</ArticleId><ArticleId IdType="pmc">PMC8641038</ArticleId><ArticleId IdType="pubmed">34909405</ArticleId></ArticleIdList></Reference><Reference><Citation>Averbuch D., Orasch C., Cordonnier C., Livermore D.M., Mikulska M., Viscoli C., Gyssens I.C., Kern W.V., Klyasova G., Marchetti O., Engelhard D., Akova M. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica. 2013;98:1826&#x2013;1835. doi: 10.3324/HAEMATOL.2013.091025.</Citation><ArticleIdList><ArticleId IdType="doi">10.3324/HAEMATOL.2013.091025</ArticleId><ArticleId IdType="pmc">PMC3856957</ArticleId><ArticleId IdType="pubmed">24323983</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfreundschuh M., Kuhnt E., Tr&#xfc;mper L., &#xd6;sterborg A., Trneny M., Shepherd L., Gill D.S., Walewski J., Pettengell R., Jaeger U., Zinzani P.L., Shpilberg O., Kvaloy S., de Nully Brown P., Stahel R., Milpied N., L&#xf3;pez-Guillermo A., Poeschel V., Grass S., Loeffler M., Murawski N. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011;12:1013&#x2013;1022. doi: 10.1016/S1470-2045(11)70235-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(11)70235-2</ArticleId><ArticleId IdType="pubmed">21940214</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberger L.M., Saltzman L.A., Senefeld J.W., Johnson P.W., DeGennaro L.J., Nichols G.L. Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies. Cancer Cell. 2021;39:1031. doi: 10.1016/J.CCELL.2021.07.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.CCELL.2021.07.012</ArticleId><ArticleId IdType="pmc">PMC8295014</ArticleId><ArticleId IdType="pubmed">34331856</ArticleId></ArticleIdList></Reference><Reference><Citation>Prior treatment with cancer drug likely renders COVID-19 vaccine ineffective, study finds | News Center | Stanford Medicine, (n.d.). https://med.stanford.edu/news/all-news/2022/02/rituximab-treatment-covid-19-mrna-vaccines.html (accessed September 17, 2022).</Citation></Reference><Reference><Citation>Shree T., Shankar V., Lohmeyer J.J.K., Czerwinski D.K., Schroers-Martin J.G., Rodriguez G.M., Beygi S., Kanegai A.M., Corbelli K.S., Gabriel E., Kurtz D.M., Khodadoust M.S., Gupta N.K., Maeda L.S., Advani R.H., Alizadeh A.A., Levy R. CD20-Targeted therapy ablates de novo antibody response to vaccination but spares preestablished immunity. Blood Cancer Discov. 2022;3:95&#x2013;102. doi: 10.1158/2643-3230.BCD-21-0222.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2643-3230.BCD-21-0222</ArticleId><ArticleId IdType="pmc">PMC9610898</ArticleId><ArticleId IdType="pubmed">35015688</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y., Xu E., Bowe B., Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat. Med. 2022;283(28):583&#x2013;590. doi: 10.1038/s41591-022-01689-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01689-3</ArticleId><ArticleId IdType="pmc">PMC8938267</ArticleId><ArticleId IdType="pubmed">35132265</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen W., Chen C., Tang J., Wang C., Zhou M., Cheng Y., Zhou X., Wu Q., Zhang X., Feng Z., Wang M., Mao Q. Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid. ) for COVID-19&#xff1a;Meta-Anal. 2022;54:516&#x2013;523. doi: 10.1080/07853890.2022.2034936.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07853890.2022.2034936</ArticleId><ArticleId IdType="pmc">PMC8820829</ArticleId><ArticleId IdType="pubmed">35118917</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso M.J., Anglin K., Durstenfeld M.S., Martin J.N., Kelly J.D., Hsue P.Y., Henrich T.J., Deeks S.G. Effect of oral Nirmatrelvir on long COVID symptoms: 4 cases and rationale for systematic studies. Pathog. Immun. 2022;7:95&#x2013;103. doi: 10.20411/PAI.V7I1.518.</Citation><ArticleIdList><ArticleId IdType="doi">10.20411/PAI.V7I1.518</ArticleId><ArticleId IdType="pmc">PMC9254867</ArticleId><ArticleId IdType="pubmed">35800257</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin M.J., Ustianowski A., De Wit S., Launay O., Avila M., Templeton A., Yuan Y., Seegobin S., Ellery A., Levinson D.J., Ambery P., Arends R.H., Beavon R., Dey K., Garbes P., Kelly E.J., Koh G.C.K.W., Near K.A., Padilla K.W., Psachoulia K., Sharbaugh A., Streicher K., Pangalos M.N., Esser M.T. Intramuscular AZD7442 (Tixagevimab&#x2013;Cilgavimab) for prevention of covid-19. N. Engl. J. Med. 2022;386:2188&#x2013;2200. doi: 10.1056/NEJMOA2116620/SUPPL_FILE/NEJMOA2116620_DATA-SHARING.PDF.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMOA2116620/SUPPL_FILE/NEJMOA2116620_DATA-SHARING.PDF</ArticleId><ArticleId IdType="pmc">PMC9069994</ArticleId><ArticleId IdType="pubmed">35443106</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>